5.54

2.58% 0.0226

Cns Pharmaceuticals Inc (CNSP)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$5.5174

Aprire:

$5.7

Volume 24 ore:

2,304

Relative Volume:

0.08

Capitalizzazione di mercato:

$8.46M

Reddito:

Utile/perdita netta:

$-16.49M

Rapporto P/E:

-0.187

EPS:

-29.6295

Flusso di cassa netto:

$-15.24M

1 W Prestazione:

-2.92%

1M Prestazione:

+11.64%

6M Prestazione:

+81.99%

1 anno Prestazione:

-9.66%

Intervallo 1D:

$5.4774

$5.79

Intervallo di 1 settimana:

$5.44

$6.1899

Portata 52W:

$1.90

$10.59

Cns Pharmaceuticals Inc Stock (CNSP) Company Profile

Nome

Cns Pharmaceuticals Inc

Settore

Healthcare (1088)

Industria

Biotechnology (605)

Telefono

1-800-946-9185

Indirizzo

2100 WEST LOOP SOUTH, HOUSTON

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

CNSP's Discussions on Twitter

Compare CNSP vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CNSP Cns Pharmaceuticals Inc	5.79	8.77M	0	-16.49M	-15.24M	-29.63
VRTX Vertex Pharmaceuticals Inc	543.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	791.31	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,029.53	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.91	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	207.93	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-12-28	Downgrade	Ladenburg Thalmann	Buy → Neutral
2020-08-24	Iniziato	Ladenburg Thalmann	Buy

Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie

Aug 19, 2026

CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com South Africa

Aug 19, 2026

Aug 18, 2026

Vertical Data: Downs Most Recently Served as CFO of CNS Pharmaceuticals >VDTA - Moomoo

Aug 18, 2026

CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock - Investing.com

Aug 18, 2026

CNS Pharmaceuticals (CNSP) director buys 2,000 shares in open-market trade - Stock Titan

Aug 18, 2026

CNS Pharmaceuticals (CNSP) CEO converts 4,750 RSUs to stock - Stock Titan

Aug 18, 2026

Aug 17, 2026

Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com

Aug 17, 2026

Aug 16, 2026

CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Trade Setups - vinanet.vn

Aug 16, 2026

Aug 14, 2026

Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan

Aug 14, 2026

Aug 13, 2026

CNSP Q2 2026 Earnings: Wider-than-Expected Loss of -$0.38 per Share Amid Clinical-Stage OperationsNet Profit Margin - vinanet.vn

Aug 13, 2026

Aug 12, 2026

CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

Aug 12, 2026

CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo

Aug 12, 2026

CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView

Aug 12, 2026

CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView

Aug 12, 2026

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com

Aug 12, 2026

CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView

Aug 12, 2026

CNS Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo

Aug 12, 2026

CNS Pharmaceuticals Q2 FY26 net loss widens 9% to $2.59 million year over year - Bitget

Aug 12, 2026

Aug 11, 2026

CNSP Q1 2026 Earnings: Loss of $7.30 Per Share Misses Estimates as Pre-Revenue Pipeline Spend Rises - vinanet.vn

Aug 11, 2026

Aug 10, 2026